

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
23 January 2003 (23.01.2003)

PCT

(10) International Publication Number
WO 03/006027 A1

(51) International Patent Classification⁷: A61K 31/565, 31/58

(21) International Application Number: PCT/IB02/03354

(22) International Filing Date: 12 July 2002 (12.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2001 01109 13 July 2001 (13.07.2001) DK
60/304,760 13 July 2001 (13.07.2001) US

(71) Applicant (for all designated States except US): SCHERRING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, 13342 Berlin (DE).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK (utility model), SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(72) Inventors; and

(75) Inventors/Applicants (for US only): SCHUERMANN, Rolf [DE/DE]; Schottmüllerstrasse 54, D, 14167 Berlin (DE). ELGER, Walter [DE/DE]; Schorlemerallee 12b, 14195 Berlin (DE).

(74) Agent: THORSEN, Jesper; Plougmann & Vingtoft a/s, Sundkrogsgade 9, P.O. Box 831, DK-2100 Copenhagen Ø (DK).

WO 03/006027 A1

(54) Title: COMBINATION OF DROSPIRENONE AND AN ESTROGEN SULPHAMATE FOR HRT

(57) Abstract: A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continuous or discontinuous administration of drospirenone and/or the estrogen sulphamate, such as weekly administration of both agents or weekly administration of the estrogen sulphamate and daily administration of the drospirenone.

COMBINATION OF DROSPIRENONONE AND AN ESTROGEN SULPHAMATE FOR HRT**FIELD OF THE INVENTION**

The present invention relates to a pharmaceutical dosage unit comprising drospirenone 5 and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate, and to methods of hormone replacement therapy by administration of drospirenone and an estrogen sulphamate to estrogen-deficient women.

BACKGROUND OF THE INVENTION

10 Estrogen plays an important role in protecting the health of women such as protecting and maintaining cardiovascular health, bone mass, and mental cognition. However, normal ageing process results in lower levels of estrogen in women and the estrogen level may be significantly reduced upon entering menopause or upon surgical removal of the uterus and/or ovaries, for which reason those women risk the development of cardiovascular 15 diseases, bone mineralisation and/or poor mental cognition. Loss of bone mineral density is the key indicator of osteoporosis.

Reduced estrogen levels have also been implicated in the development of urinary incontinence as a result of the effect of the loss of estrogen on the smooth muscle cells of 20 the urethra. Reduced estrogen levels may also be implicated in significant weight and fat mass gain in postmenopausal women.

Hormone replacement therapy has aimed to improve the quality of life of women during this natural ageing process to alleviate symptoms associated with this time of transition 25 and to reduce the likelihood or slow the progression of disorders and diseases associated with reduced estrogen activity.

One principal aim of hormone replacement therapy is to restore levels of the sex steroid hormones in naturally or prematurely pre-menopausal, menopausal and post-menopausal 30 women or to establish these levels in hypogonadal females.

One form of hormone replacement therapy relates to monotherapy, also referred to as unopposed therapy, wherein the woman is treated with estrogens alone. However, exogenous estrogens stimulate the proliferation of the endometrium, which may result in 35 in the development of hyperplasia, a risk factor for endometrial cancer.

A second form of hormone replacement therapy relates to combination therapy, also referred to as opposed therapy, wherein the woman is treated with a combination of an estrogen and a progestagen. Advantageously, the progestogen protects the endometrium from hyperplasia.

5

However, the use of natural progesterone in combination therapy is limited by the low bioavailability of natural progesterone, even in micronized form. Significantly, it has been found that combination therapy comprising the use of drospirenone as a progestogen, is remarkably effective. Drospirenone (drospirenone), a 17- α -spirolactone derivative, is a

10 synthetic progestagen that has a surprisingly similar physiological profile to progesterone yet notably better bioavailability. It is the first synthetic progestagen to have a progesterone-like pharmacological profile in that it has antiestrogenic, antiandrogenic and anti-mineralcorticoid activity.

15 The progestogenic activity of drospirenone and its consequent utility as a contraceptive agent at dosage levels of 0.5-50 mg is disclosed in DE 30 22 337. The anti-mineralcorticoid activity of drospirenone limits the increase in weight gain that is observed in women taking estrogens by reduction of the estrogen-induced sodium and water retention. The anti-mineralcorticoid effect is also known to have beneficial and preventive effects on
20 hypertension. The anti-androgenic activity of drospirenone may suppress unwanted symptoms such as acne and changes in hair pattern, hair distribution, and hair growth such as in hirsutism, by inhibiting androgenic receptors in the skin. The pharmacological activities of drospirenone is described in Krattenmacher, Rolf, *Contraception* (62) 2000, pp 29-38 ; *Drospirenone: pharmacology and pharmacokinetics of a unique progesterone*. The
25 activity of drospirenone is further described in *Drugs of the Future* 2000, 25(12), pp 1247-1256.

Drospirenone is also known from DE 26 52 761 in which its use as a diuretic is disclosed.

30 The use and role of progestogens in opposed forms of hormone replacement therapy has been studied by the scientific community (Lobo R.A., 1992; Sobel N.B., 1994) as have been regimens comprising estrogens and progestogens (Corson S.L., 1993; Jones K.P., 1992).
35 Various regimens for hormone substitution have been disclosed. For example the use of a preparation for hormone substitution therapy comprising at least one progestagen and at least one estrogen wherein the estrogen dose varies with a periodicity such that blood loss is substantially avoided is disclosed in WO 95/07081. Furthermore, a regimen involving

interrupted administration of progestin in the presence of continuous estrogen is disclosed (Casper R.F. et al., Am J Obstet. Gynecol. vol 168, no 4, p 1188 - 1983).

The use of a therapeutic gestagen such as drospirenone, possibly in combination with an
5 estrogen for the treatment of Premenstrual Dysphoric Disorders (PMDD) is disclosed in WO
98/27929.

Also various pharmaceutical compositions comprising drospirenone have been reported, for
example, a pharmaceutical composition comprising a combination of ethinyl estradiol and
10 drospirenone for use as a contraceptive is disclosed in WO 01/15701.

Estrogen sulphamates, such as estradiol sulphamate, may be viewed as prodrugs, which,
upon enzymatic hydrolysis by sulphatases *in vivo*, are split into the estrogen, such as
estradiol, and a sulphamic acid. The use of estrogen sulphamates for oral discontinuous
15 application for hormone replacement therapy is disclosed in WO 00/06175. The
discontinuous method of administration is such that the administration can take place at
intervals ranging from 2 to 40 days. WO 00/06175 also relates to the additional
administration of gestagens, preferably continuously in the form of an implant or in the
form of an intrauterine releasing system.

20

Estradiol sulphamates were first disclosed in WO 93/05064 in connection with the findings
that estrone sulphamates showed excellent sulphatase inhibiting activity for which reason
it may be used in the treatment of estrone dependent tumors, especially breast cancer.

25 The invention relates to the use of a combination of drospirenone and an estradiol
sulphamate in hormone replacement therapy.

SUMMARY OF THE INVENTION

The present investigators have found that the particular combination of an estrogen
30 sulphamate and drospirenone is remarkably effective for use in hormone replacement
therapy.

Thus, in a first aspect, the invention relates to a pharmaceutical composition in the form of
a dosage unit comprising a combination of an estrogen sulphamate and drospirenone
35 together with one or more pharmaceutically acceptable carriers or excipients. In a
presently preferred embodiment, the estrogen sulphamate is the unsubstituted 17-
estradiol-sulphamate.

A second aspect of the present invention relates to the use of a combination of drospirenone and an estrogen sulphamate for the preparation of a medicament comprising a sufficient dose of the estrogen sulphamate for the treatment of diseases, disorders or symptoms associated with deficient endogenous levels of estrogen in a woman.

5

Correspondingly, a method of treating diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in a woman comprising administering a sufficient dose of estrogen sulphamate to alleviate said diseases, disorders and symptoms in combination with drospirenone. Thus, the method comprises the administering of an

10 estrogen sulphamate in sufficient amounts to alleviate said diseases, disorders and symptoms and drospirenone.

A still further aspect of the invention relates to a pharmaceutical kit comprising up to 70 dosage units or multiples thereof, wherein at least 3 said dosage units within one multiple
15 of units comprise an estrogen sulphamate and at least 3 said dosage units within one multiple of units comprise drospirenone and wherein optionally up to 64 of said dosage units within one multiple of units comprise a placebo or a blank.

DETAILED DESCRIPTION OF THE INVENTION

20 The term "an estrogen sulphamate" is intended to mean one or more sulphamate esters of an estra-1,3,5(10) triene and pharmaceutically acceptable salts thereof, wherein the triene has at least one hydroxy group. More specific, an estra-1,3,5(10) triene may contain one, two or three free hydroxyl groups. In suitable embodiments of the invention, such trienes is an estrone, an estradiol or an estriol, preferably an estradiol or an estriol. The
25 term "sulphamate ester" is intended to mean an ester with sulphamic acid or with N- substituted sulphamic acid, wherein the N-substituted sulphamic acid may be an N-alkyl, N-cycloalkyl, N-alkenyl or an optionally substituted N-aryl. The N-alkyl, N-cycloalkyl and N- alkenyl may consist of up to 7 carbon atoms, but 1, 2 , 3, or 4 carbonatoms are preferred. The optionally substituted N-aryl relates to where one or more hydrogen atoms are
30 replaced by an alkyl, a cycloalkyl or an alkenyl. The alkyl, cycloalkyl and alkenyl may consist of up to 7 carbon atoms, but 1, 2 , 3, or 4 carbonatoms are preferred. In general, the N-substituted sulphamic acid may be selected from the group comprising N-alkyl, N- cycloalkyl, N-alkenyl and N-aryl derivatives of sulphamic acid as described in patent WO 93/05064.

Moreover, the term "an estrogen sulphamate" relates also to sulphamate esters of conjugated estrogens.

5 In specific embodiments of the invention, the estrogen sulphamate is a 17-estradiol, a derivative or a pharmaceutically acceptable salt thereof esterified with sulphamic acid or a N-substituted sulphamic acid. In other embodiments of the invention, the estrogen sulphamate is an estriol or an estrone their derivatives or pharmaceutically acceptable salts esterified with sulphamic acid or with N-substituted sulphamic acid.

10

In preferred embodiments the esterification is at the C-3 hydroxyl of said estra-1,3,5(10) triene such as at the C-3 hydroxyl group of estrone, estradiol or estriol.

Preferred estrogen sulphamates are selected from the group comprising of the
15 unsubstituted 17-estradiol-sulphamate, unsubstituted 16,17-estriol-sulphamate, 17-estradiol-3-N,N-dimethyl sulphamate and 16,17-estriol-3-N,N-dimethyl sulphamate, most preferably the unsubstituted 17-estradiol-sulphamate.

Moreover, in some embodiments two or more different estrogen sulphamates may be
20 used.

The term "administration" relates to the application or consumption of a dosage unit. The term "delivery" relates to the *in vivo* absorption of a therapeutically active amount of an agent.

25

The term "continuous" is intended to relate to the delivery of an agent at an interval period, wherein delivery of the agent is maintained for the duration of the interval period. For example, the administration every day of the agent in a dosage effective throughout the daily interval, the administration every third day of the agent in a dosage effective
30 throughout the 3 day interval, the administration every week of a dosage effective throughout the 7 day interval, or the administration every month of a dosage effective throughout the one month interval. Furthermore, continuous delivery may involve administration of an agent for three days followed by three days of no administration such as 3-days-on-3-days-off administration, which in the case of continuous delivery may
35 result in at least 6 days delivery of an agent. Likewise, continuous delivery of an agent upon administration in a 7-days-on-7-days-off manner may result in at least 14 days delivery of an agent.

The term "discontinuous" involves the interrupted delivery of an agent, wherein the period of interruption is not equivalent to the period of delivery or to the duration of the effect of an agent. The administration of an agent every third day delivering an effective dosage throughout only 1 day or 2 days are typical discontinuous regimens of 1-day-on-2-days-off and 2-days-on-1-day-off, respectively. Discontinuous delivery involving administration of an agent once a week as a 1-day-on-6-days-off, 3-days-on-4-days-off, 2-days-on-5-days-off are typical discontinuous delivery regimens. Another discontinuous delivery involves delivery of an agent for 21 days followed by a period of interruption for 7 days as a 21-days-on-7-days-off cycle. Typical examples of such a cycle include administration or delivery of an agent for 21 days followed by 7 days of no administration or delivery of an agent; and weekly administration of an agent for delivery of agent throughout the week for 3 weeks followed by one week of no administration of agent.

Furthermore, discontinuous delivery may involve administration of an agent for three days followed by three days of no administration such as 3-days-on-3-days-off administration, which in the case of discontinuous delivery may result in 3 to 5 days delivery of an agent. Likewise, discontinuous delivery of an agent upon administration in a 7-days-on-7-days-off manner may result in 7 to 13 days delivery of an agent. The period of interruption relates to the period, wherein an agent is not delivered.

20

A sequential administration may result in discontinuous or continuous delivery of an agent. An example of a sequential administration resulting in a continuous delivery is the weekly administration of an agent effective for the duration of the week. An example of a sequential administration resulting in a discontinuous delivery is a monthly administration of an agent effective for only 21 days.

The term "interval" in connection with the treatment is intended to relate to the period of time between administration of an agent such as the number of days between taking an oral formulation, applying a new transdermal patch, (self)-administering an injection. Each administration is that of a dosage unit.

Accordingly, in the embodiment that an oral formulation comprising an estrogen sulphamate and drospirenone is administered every week and delivers the sulphamate for a 7-day period and drospirenone for a 3-day period, the estrogen sulphamate is delivered in a continuous manner and drospirenone is delivered in a discontinuous manner. The administration of the dosage unit is said to be on a weekly interval. Similarly, a monthly-administered transdermal patch that delivers the estrogen sulphamate for a month and drospirenone for 3 weeks delivers the estrogen sulphamate in a continuous manner and drospirenone in a discontinuous manner.

In the present context, the term cycle itself or when associated with the term menstrual is intended to mean the number of days between menses in a woman. It can range from 21-35 days, typically 28 days.

5

In the present context, the term menopause is understood as the last natural (ovary-induced) menstruation. It is a single event and a result of an age-dependent dysfunction of the ovarian follicles. Menopause results from the ovaries decreasing their production of the sex hormones estrogen and progesterone. When the number of follicles falls below a 10 certain threshold (a bleeding threshold), the ovaries can no longer produce mature follicles and sex hormones. The ability to reproduce ends with menopause.

The peri-menopausal phase begins with the onset of climacteric symptoms when the cycle becomes irregular and ends one year after menopause. The end of peri-menopausal phase 15 can be identified after a protracted period of time without bleeding. Post-menopause is the phase that begins at menopause and continues until death.

As stated, a first aspect of the invention relates to a pharmaceutical dosage unit in the form of a dosage unit comprising a combination of an estrogen sulphamate and 20 drospirenone together with one or more pharmaceutically acceptable carriers or excipients.

In a particularly preferred embodiment of the invention, the dosage unit is administered weekly, such as a combined continuous administration. In a particularly preferred embodiment of the present invention, a dosage unit comprising estrogen sulphamate and 25 drospirenone is administered weekly.

An alternative suitable embodiment, an estrogen sulphamate is administered weekly whereas drospirenone is administered daily. In a further suitable embodiment, both the estrogen sulphamate and drospirenone are administered daily.

30

According to the invention, the dosage unit may comprise estrogen sulphamate in a dose sufficient for the treatment of diseases, disorders or symptoms associated with deficient endogenous levels of estrogen in a woman. Typically, the deficient endogenous levels of estrogen are caused by natural menopause, pre-menopause, peri-menopause, post-35 menopause, hypogonadism, castration, hysterectomy, or primary ovarian failure.

As mentioned the dosage unit comprises drospirenone. The dose of drospirenone may be in a dose sufficient to exhibit its anti-androgenic and/or anti-mineralcorticoid activity in that it should be understood that the anti-androgenic and/or anti-mineralcorticoid activity

relates to prevention or counteraction of the adverse effects of the estrogen sulphamate, such as adverse effects to the endometrium; prevention or lessening of weight gain; prevention or lessening of changes in hair pattern, texture, growth or distribution, such as in hirsutism.

5

In a suitable embodiment of the invention, the dose of an estrogen sulphamate present in a dosage unit intended for daily delivery of about 0.01 to 1 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.02 to 1 mg or 0.04 to 0.8 mg, more preferably of about 0.06 to 0.6 mg, most preferably of about 0.06 to 0.4 mg of the unsubstituted 17-estradiol-sulphamate.

10 The dose of drospirenone present in a dosage unit of a dosage unit intended for daily administration is suitably about 0.1 mg - 5 mg, preferably 0.25 to 4 mg, more preferably 0.5 to 3 mg, particularly preferably 0.5 to 2.5 mg, even more preferably about 0.5 to 1.5 mg, most preferably about 0.5 to 1 mg.

15 Accordingly, the dose of an estrogen sulphamate in a dosage unit intended for a three-day delivery corresponds to about 0.03 to 3 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.06 to 3 mg or of about 0.1 to 2.5 mg, more preferably of about 0.2 to 1.5 mg, most preferably of about 0.2 to 1 mg of the unsubstituted 17-estradiol-sulphamate.

20 The dose of drospirenone in a dosage unit intended for a three-day delivery is typically about 0.25 mg to 15 mg, preferably 0.75 mg to 10 mg, particularly about 1 to 5 mg, such as 1, 2, 3, 4, or 5 mg most preferably about 2 to 3 mg.

25 In a particularly interesting embodiment of the present invention, the dosage unit is administered weekly. In such an embodiment, the dose of estrogen sulphamate in a dosage unit intended for a weekly administration typically corresponds to about 0.1 to 6 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.25 to 6 mg or about 0.25 to 4 mg, more preferably of about 0.25 to 3 mg, most preferably of about 0.25 to 2.5 mg or about 0.25 mg to 2 mg of the unsubstituted 17-estradiol-sulphamate.. The dosage unit intended for weekly administration typically comprises drospirenone in a dose of about 1 mg to 20 mg, preferably 2 mg to 10 mg, more preferably about 2 to 8 mg, most preferably about 3 to 6 mg, such as 3, 4, 5, or 6 mg, most particularly about 4 mg.

30 The suitable dose of estrogen sulphamate in a dosage unit intended for administration corresponding to a full-cycle administration corresponds to a delivery of about 0.4 to 25 mg of the unsubstituted 17-estradiol-sulphamate per cycle, preferably of about 0.8 to 16

mg, more preferably of about 0.8 to 12 mg, most preferably of about 0.8 to 10 mg of the unsubstituted 17-estradiol-sulphamate.

The dose of drospirenone in a dosage unit intended for delivery corresponding to a
5 menstrual cycle is suitably about 2 to 76 mg per cycle, preferably about 5 mg to 50 mg of
drospirenone, more preferably about 8 to 30 mg, even more preferably about 10 to 25 mg,
most preferably 12 to 20 mg per cycle.

In an interesting embodiment of the dosage unit of the present invention, drospirenone is
formulated for slow release, a modified -release of the agent. Similarly, the estrogen
10 sulphamate may also be formulated for slow release.

However, as is known to the person skilled in the art, an estrogen sulphamate has a
sustained effect *in vivo*, attributed at least in part to the slow hydrolysis of the sulphamate
ester to generate estradiol. This is one advantage of the use of an estrogen sulphamate
15 over other estrogens. An estradiol sulphamate is carried by erythrocytes and avoid hepatic
metabolism. Thus, lower doses may be required. Moreover, as demonstrated by the
present investigator, an estrogen sulphamate inhibits sulphatases *in vivo* thus slowing the
hydrolysis of the sulphamate ester, thus resulting in a slow release of estrogen from the
estrogen sulphamate, resulting in a prolonged effect of the estrogen sulphamate *in vivo*.

20 An important object of the invention relates to the prolonged effect of drospirenone and an
estrogen sulphamate upon administering the said agents from a suitable formulated
dosage unit. The dosage unit of the present invention may be formulated such that a
dosage unit is formulated for delivery of drospirenone in a sufficient dose to counteract or
25 protect from the adverse effects of an estrogen sulphamate such as the adverse effects to
the endometrium or in a dose sufficient for exhibiting its anti-androgenic and/or anti-
mineralcorticoid activities for a period of 1 day, 3 days, 7 days, 14 days, 28 days or 1
month after administration of one of said dosage unit.

30 Thus, apart from other, the advantages of low required doses of the estrogen sulphamate
and prolonged effect of the estrogen sulphamate, such as for a week, a further advantage
of the present invention is that the upper limit of the low doses of an estrogen sulphamate
need not be limited for fear of resulting in hyperplasia of the endometrium. Drospirenone
may be present in an amount sufficient to counter the possible adverse effects of the
35 estrogen sulphamate or in therapeutically sufficient anti-mineralcorticoid and/or anti-
androgenic amounts. Similarly, the dosage unit of the present invention may be
formulated such that the dosage unit of the estrogen sulphamate is delivered *in vivo* in
sufficient a dose to treat diseases, disorders or symptoms associated with deficient

endogenous levels of estrogen in a woman throughout a period selected from 1 day, 3 days, 7 days, 14 days, 28 days or 1 month after administration of one of said dosage unit.

Hence, in suitable embodiments of the invention, the dosage unit of the invention may be 5 formulated such that the dose of the estrogen sulphamate and the drospirenone is delivered throughout a period of 1 day, 3 days, 7 days, 14 days, 28 days or 1 month after administration of one of said dosage unit.

The dosage unit may be formulated for oral, topical, transdermal, subcutaneous or 10 parenteral administration. In a preferred embodiment, the dosage unit is formulated for oral, transdermal, transvaginal or subcutaneous administration. Moreover, in a presently preferred embodiment, the dosage unit is formulated for oral administration. Typically, the oral formulation is in the form of tablets, capsules, granules or powders, and the transdermal formulation is implantation tablets, oils or implants.

15

The dose of an estrogen sulphamate may vary from woman to woman, depending on the phase of her life (pre-, peri- or post-menopausal), endogenous levels of estrogen, the severity of the symptom(s), disorder or disease, the particular disorder, disease or symptom targeted, the use by the woman of other medicaments for other purposes, and 20 other pharmacokinetic variables.

The dose of an estrogen sulphamate may also be selected so as to obtain beneficial effects on cognitive functions, depression and CNS disorders such as degenerative CNS disorders in the peri- and post-menopausal woman.

25

Typical diseases, disorders and symptoms associated with deficient levels of endogenous levels of estrogen are hot flushes, sweating attacks, palpitations, sleep disorders, mood changes, nervousness, anxiety, poor memory, loss of confidence, loss of libido, poor concentration, diminished energy, diminished drive, irritability, urogenital atrophy, atrophy 30 of the breasts, cardiovascular disease, changes in hair distribution, thickness of hair, changes in skin condition, breast cancer, bone demineralisation and osteoporosis. The prevention or management of osteoporosis and bone demineralisation is a particularly interesting application of the dosage unit of the present invention.

35 Other than osteoporosis, further particularly interesting indications for use of the dosage unit are the for the alleviating of sleep disorders, mood changes, nervousness, anxiety, urogenital atrophy, atrophy of the breasts and for the prevention of breast cancer. The prevention of breast cancer by the dosage unit of the invention is thought to be associated with the interference of estrogen sulphamate with sulphatase. Thus, the invention

relates to a dosage unit, wherein the estrogen sulphamate is present in an amount sufficient for the treatment of breast cancer in a woman, such as estrogen-dependent breast cancer.

- 5 Deficient levels of estrogen can occur for a variety of reasons. The dosage unit can be such that it is adequate for deficient levels of estrogen, regardless of the cause. Causes anticipated by the therapy are, but not limited to, natural menopause, pre-menopause, peri-menopause, post-menopause, hypogonadism, castration or primary ovarian failure.
- 10 Low endogenous levels of estrogen, irrespective of the cause, lead to an overall decreased quality of life for women. Symptoms, diseases and disorders range from merely being inconvenient to life threatening. The dosage unit of this therapy anticipates the effective alleviation of all psychological signs of estrogen deficiency.
- 15 Transient symptoms, such as vasomotor signs and psychological symptoms are certainly embodied with the realm of therapy. Vasomotor signs comprise but are not limited to hot flushes, sweating attacks such as night sweats, and palpitations. Psychological symptoms of estrogen deficiency comprise, but are not limited to, insomnia and other sleep disorders, poor memory, loss of confidence, mood changes, anxiety, loss of libido, difficulties in
- 20 concentration, difficulty in making decisions, diminished energy and drive, irritability, and crying spells.

The treatment of the aforementioned symptoms can be associated with the peri-menopausal phase of a woman's life or after, sometimes long after menopause. It is

- 25 anticipated that the invention is applicable to these and other transient symptoms during the peri-menopausal phase, menopause, or post-menopausal phase. Moreover, the aforementioned symptoms can be alleviated if the cause of the estrogen deficiency is hypogonadism, castration or primary ovarian failure.
- 30 In another embodiment of the invention, the therapy is used for the treatment of permanent effects of estrogen deficiency. Permanent effects comprise physical changes such as urogenital atrophy, atrophy of the breasts, cardiovascular disease, changes in hair distribution, thickness of hair, changes in skin condition and osteoporosis.
- 35 Urogenital atrophy, conditions associated with it such as vaginal dryness, increase in vaginal pH and subsequent changes in flora, or events which lead to such atrophy, such as decreases in vascularity, fragmentation of elastic fibres, fusion of collagen fibres, or decreases in cell volume are symptoms thought to be particularly relevant to this therapy. Furthermore, the invention is thought to be relevant to other urogenital changes

associated estrogen deficiency such as decreases in the length and/or diameter of the vagina, decreases mucus production, changes in cell population, decreases in glycogen production, decreases in growth of lactobacilli or increases in growth of *streptococci*, *staphylococci*, or *coliform bacilli*. Other associated changes that are thought to be

5 preventable by the invention are those that may render the vagina susceptible to injury or infection, such as exudative discharges, vaginitis, and dyspareunia. Furthermore, infections of the urinary tract and incontinence are other common symptoms associated with lowered estrogen levels.

10 Other embodiments of the invention include the prevention or alleviation of physical changes associated with estrogen deficiency, such as changes in the skin, changes in hair distribution, thickness of hair, atrophy of the breasts, or osteoporosis.

The invention includes prevention of negative effects on the cognitive function and other
15 central nervous parameters related to estrogen deficiency.

The prevention and management of osteoporosis, most notably post-menopausal
osteoporosis, is a particularly interesting embodiment of the invention. Furthermore, bone
demineralisation, reduction of bone mass and density, thinning and interruption of
20 trabeculae, and/or consequent increase in bone fractures or bone deformations are
thought to be particularly relevant. The prophylactic treatment of osteoporosis is an
interesting therapeutic application of the invention.

The amount of drospirenone (drospirenone) in a dosage unit may depend on the dose of
25 an estrogen sulphamate. For instance, at high doses of estrogen sulphamate, the dose of
DRPS may be such that to be sufficient to protect the endometrium from the adverse
effects of the levels of the estrogen and an estrogen sulphamate in the woman.
Drospirenone, in sufficient doses, may be used as an opponent to estrogen to protect the
endometrium from hyperplasia and/or cancer. Drospirenone may also be present in the
30 dosage unit in relation to its combined therapeutic anti-mineralcorticoid and/or-androgenic
properties and/or anti-ovulatory activities. According to said activities, drospirenone may
balance the potential weight gain and potential hypertension that may follow the intake of
estrogens in women. Also the activities of drospirenone on suppression of unwanted
symptoms such as acne and hirsutism may be beneficial for peri-menopausal or post-
35 menopausal women. Accordingly, the invention relates to a dosage unit, wherein
drospirenone is in an amount sufficient to exhibit its anti-androgenic and/or anti-
mineralcorticoid activity.

The anti-androgenic and/or anti-mineralcorticoid activity may be selected from the group consisting of prevention or counteraction of the adverse effects of an estrogen sulphamate, such as adverse effects to the endometrium; prevention or lessening of weight gain; prevention or lessening of changes in hair pattern, texture, growth, distribution, such as in 5 hirsutism.

Drospirenone may be administered in the form of an ester or prodrug such as administered as an oxyiminopregnane carbolactone as disclosed in WO 98/24801. This prodrug to drospirenone is converted *in vivo* to drospirenone.

10

Given drospirenone is not particularly amenable to transdermal delivery, in one embodiment of the invention, drospirenone is administered as an oxyiminopregnane carbolactone transdermally. In such an embodiment, an estrogen sulphamate may, for instance, be administered transdermally or orally.

15

The suitable dose according to the invention may depend on the dose required of an estrogen sulphamate, such as at low doses of an estrogen sulphamate, the adverse effects of the estrogen sulphamate are minimised, thus the amount of drospirenone may be reduced, but still be in an amount sufficient to provide any anti-androgenic and/or anti- 20 mineralocorticoid activity *in vivo*.

The dosage unit formulated for oral administration may be a solid, semisolid or fluid formulation. The solid dosage units may be selected from the group consisting of uncoated tablets, modified-release tablets, gastro-resistant tablets, orodispersible tablets, 25 effervescent tablets, chewable tablets, soft capsules, hard capsules, modified-release capsules, gastro-resistant capsules, uncoated granules, effervescent granules, coated granules, gastro-resistant granules, modified -release granules, and powders for oral administration; and the fluids are selected from the group consisting of solutions, suspensions and emulsions.. The dosage units for topical administration may be selected 30 from the group consisting of creams, gels, emulsions, suspensions, lotions, suppositories, enemas, pessaries, vaginal capsules, vaginal tablets, pads, sponges, plasters and transdermal delivery systems. The dosage units for parenteral administration may be selected from the group consisting of solutions, suspensions, emulsions, gels, implantation tablets and implants.

35

The use of a combination of the estrogen sulphamate and drospirenone may be such that the active agents are administered concomitantly or independently. That is to say that the combination is administered in a single dosage form or as more than one dosage form such as one agent administered as a solid and the other agent as a fluid. Similarly, one

agent may be formulated for oral administration whilst the other is formulated for transdermal or subcutaneous administration. In a preferred embodiment, both agents are administered as solids formulated for oral administration.

- 5 The combination of an estrogen sulphamate and/or drospirenone may be administered in oral, topical, transdermal, subcutaneous, transvaginal or parenteral formulation, or mixtures thereof. The estrogen and/or drospirenone may be administered as an oral formulation, such as a tablet, from a patch, from an implant or combinations thereof. In a preferred embodiment, an estrogen sulphamate and/or drospirenone are administered in
- 10 oral formulation or transdermal formulation, preferably oral formulation. In a suitable embodiment, estrogen is administered as an oral formulation and drospirenone is administered as oral or transdermal formulation, preferably an oral formulation.

Moreover, an interesting embodiment of the invention comprises a dosage unit wherein the
15 drospirenone (drospirenone) is in micronized form, such that one or both estrogen and drospirenone are in micronized form, preferably both estrogen and drospirenone are in micronized form.

Drospirenone, which may be prepared substantially as described in US 4,129,564 or WO
20 98/06738, is a sparingly soluble substance in water and aqueous buffers at various pH values. Furthermore, drospirenone is rearranged to an inactive isomer under acid conditions and hydrolysed under alkaline conditions. To ensure good bioavailability of the compound, it is therefore advantageously provided in a form that promotes rapid dissolution thereof.

25

It has been found that when drospirenone is provided in micronized form in a pharmaceutical dosage unit, rapid dissolution of the active compound from the dosage unit occurs *in vitro*. A micronized substance is such that a test batch (ca. 200 mg) of the particles, herein drospirenone particles, has a surface area of more than 10,000 cm²/g,
30 and has the following particle size distribution for drospirenone as determined under the microscope: not more than 2 particles in a given batch (ca. 200 mg) with a diameter of more than 30 µm, and preferably ≤ 20 particles with a diameter of ≥ 10 µm and ≤ 30 µm. The term "rapid dissolution" is defined as the dissolution of at least 70% over about 30 minutes, in particular at least 80% over about 20 minutes, of drospirenone from a tablet
35 preparation containing 3 mg of drospirenone in 900 ml of water at 37°C determined by the USP XXIII Paddle Method using a USP dissolution test apparatus 2 at 50 rpm.

As an alternative to providing the drospirenone in micronized form, it is possible to dissolve it in a suitable solvent, e.g. methanol or ethyl acetate, and spray it onto the

surface of inert carrier particles followed by incorporation of the particles containing drospirenone on their surface in the dosage unit. Another suitable administration of drospirenone is in the form of a cyclodextrin complex.

- 5 The dosage unit of the present invention comprises carriers or excipients, which may act to promote dissolution of both active substances. Examples of such carriers and excipients include substances that are readily soluble in water such as cellulose derivatives, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, gelled starch, gelatin or polyvinylpyrrolidone. In particular, it is anticipated that
- 10 polyvinylpyrrolidone might be particularly helpful to promote dissolution.

The term "pharmaceutically acceptable carriers and excipients" is intended to mean substances, which are substantially harmless to the individual to which the dosage unit will be administered. Such an excipient normally fulfils the requirements given by the national

- 15 drug agencies. Official pharmacopeias such as the British Pharmacopeia, the United States of America Pharmacopeia and the European Pharmacopeia set standards for well-known pharmaceutically acceptable excipients.

Suitable pharmaceutically acceptable excipients according to the invention include all kinds

- 20 that may be used for solid, semi-solid and fluid dosage units.

The excipients may include solvents, buffering agents, preservatives, humectants, chelating agents, antioxidants, stabilizers, emulsifying agents, suspending agents, gel-forming agents, diluents, disintegrating agents, binding agents, lubricants, coating agents

- 25 and wetting agents. Typically, the diluents and disintegrating agents may be lactose, saccharose, emdex, calcium phosphates, calcium carbonate, calcium sulphate, mannitol, starches and microcrystalline cellulose.

Binding agents are but not limited to saccharose, sorbitol, gum acacia, sodium alginate,

- 30 gelatine, starches, cellulose, sodium carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone and polyethyleneglycol.

Typically wetting agents may be sodium laurylsulphate and polysorbate 80, and lubricants may be talcum, magnesium stearate, calcium stearate, silicium oxide, precirol and

- 35 polyethyleneglycol.

Coating agents are but not limited to hydroxypropylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, ethylcellulose and polymethylacrylates.

The dosage unit may also be administered transdermally, e.g where the dosage unit is formulated as a pad, dressing, bandage, plaster or transdermal delivery systems. Suitable pharmaceutically acceptable carriers and excipients includes microspheres and liposomes.

5

As stated, a second aspect of the invention relates to the use of a combination of drospirenone and an estrogen sulphamate for the preparation of a medicament comprising a sufficient dose of the estrogen sulphamate for the treatment of diseases, disorders or symptoms associated with deficient endogenous levels of estrogen in a woman. Preferably,

- 10 the medicament comprises drospirenone in a sufficient dose to counteract or protect from the adverse effects of an estrogen sulphamate such as adverse effects to the endometrium, or in an amount sufficient for exhibiting its anti-androgenic and/or anti-mineralcorticoid activities. Correspondingly, a method of treating diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in a woman comprising
- 15 administering an sufficient dose of estrogen sulphamate to alleviate said diseases, disorders and symptoms in combination with drospirenone is anticipated. Thus, the method comprises the administering of an estrogen sulphamate in sufficient amounts to alleviate said diseases, disorders and symptoms and drospirenone.
- 20 According to the invention, drospirenone and/or the estrogen sulphamate may be delivered in a continuous or discontinuous manner. In a suitable embodiment of the present invention, drospirenone is administered in a continuous manner comprising intervals of administration 1 to 30 days, preferably 1, 3, 7, 14, 28 or 30 days, most preferably 1, 7, 28, or 30 days. In a presently preferred embodiment, drospirenone is administered every
- 25 1 day.

In a further suitable embodiment of the present invention, drospirenone is delivered in a discontinuous manner such as delivery for 1 day followed by an interruption for 1 to 30 days; delivery for 2 days followed by an interruption for 1 to 29 days, delivery for 3 days

- 30 followed by an interruption for 1 to 28 days, delivery for 4 days followed by an interruption for 1 to 27 days, delivery for 5 days followed by an interruption for 1 to 26 days, delivery for 6 days followed by an interruption for 1 to 25 days; delivery for 7 days followed by an interruption for 1 to 24 days; delivery for 10 days followed by an interruption for 1 to 21 days; delivery for 14 days followed by an interruption for 1 to 17 days; delivery for 17
- 35 days followed by an interruption for 1 to 14 days; delivery for 21 days followed by an interruption for 7 to 10 days; or combinations thereof.

In a particularly interesting embodiment, drospirenone is delivered in a discontinuous manner such as delivery every third day, such as a 1-day-on-2-days-off regimen. This may

be achieved by a regimen comprising administering a dosage unit comprising an estrogen sulphamate and drospirenone every third day and administering a dosage unit comprising an estrogen sulphamate but essentially absent in drospirenone on the other days of the regimen. Alternatively, an estrogen sulphamate may be delivered throughout the interval 5 of the three days.

In a typical embodiment of the invention, the estrogen sulphamate is delivered in a continuous manner that may be effected by administration of a dosage unit at regular intervals e.g. 1 day, 3 days, 6 days, 7 days, 14 days, 28 days, 1 month, 3 months, 6 10 months, 9 months or 12 months. In a preferred embodiment, the estrogen sulphamate is delivered in a continuous manner comprising intervals of administration of 1 to 30 days, preferably 1, 3, 7, 14, 28 or 30 days, most preferably 1, 7, 28 or 30 days. In a presently preferred embodiment, the estrogen sulphamate is administered every 7 days.

15 In another typical embodiment of the invention, the estrogen sulphamate is delivered in a sequential manner, such as wherein the estrogen sulphamate is delivered for 18-30 followed by an interruption of delivery of 5-13 days; delivered for 19-28 days followed by an interruption of delivery of 6-12 days; or delivered for 21 days followed by an interruption of delivery of 7 -10 days.

20 A particularly embodiment of the invention includes the use of the combination of an estrogen sulphamate and drospirenone by administering both agents by means of oral administration. Further interesting aspects thereof includes the oral administration of drospirenone combined with transdermal, transvaginal or parenteral administration of an 25 estrogen sulphamate. Combinations of transdermal administration and parenteral administration is also of interest.

The regimen may involve either the concomitant administration of an estrogen sulphamate and drospirenone or the independent administration of an estrogen sulphamate and 30 drospirenone in a continuous or discontinuous manner.

An interesting embodiment of the regimen involve the delivery of an estrogen sulphamate in a continuous manner and drospirenone in a discontinuous manner, such regimen consisting of administering a dosage unit daily such that an estrogen sulphamate is 35 delivered daily and drospirenone is delivered every second, third, or fourth, fifth, sixth or seventh day, preferably every third day. This may be accomplished by weekly administering a dosage unit comprising an estrogen sulphamate for a delivery of estrogen throughout that weekly interval and administering a dosage unit comprising drospirenone weekly, daily, or every 2, 3, 4, 5, or 6 days.

Hormone replacement therapy may be required for the remainder of the life of the woman experiencing deficient levels of estrogen. The treatment involves administration of a combination of estrogen sulphamate and drospirenone over the course of a cycle according to an array of regimens depending on the needs of the woman. A regimen is typically related to a cycle regardless of whether a natural cycle actually exists in the woman. The method of treatment of the diseases, disorders or symptoms associated with deficient endogenous levels of estrogen in a woman involves administering the combination typically for a multiple of cycles, such as administering the combination for 1 to 12 cycles, preferably 2 to 6, such as 2, 3, 4, 5, and 6 multiples of 28 to 35 days. This may involve the administration of daily dosage units for each day of the 1 to 12 cycles.

A further aspect of the present invention relates to a kit for providing the sufficient dosages of the combination throughout the cycle. The kit may comprise an oral formulation of one or both agents. The kit may comprise an oral formulation of one agent and a topical, transdermal, subcutaneous, transvaginal or parenteral formulation of the other agent. Typically, the kit comprises an oral formulation of both agents. The oral formulations may be such that one agent is delivered in a continuous manner and the other agent is delivered in a discontinuous manner.

The kit is typically designed to increase patient-compliance to follow the regimen.

Thus, an interesting aspect of the invention relates to a pharmaceutical kit comprising up to 70 dosage units or multiples thereof, wherein at least 3 said dosage units within one multiple of units comprise an estrogen sulphamate and at least 3 said dosage units within one multiple of units comprise drospirenone; and wherein optionally up to 64 of said dosage units within one multiple of units comprise a placebo or a blank.

The term "multiples thereof" is denoted to mean replicates of a set of dosage units. For example a set of 70 dosage units may be replicated into 140, 210, 280 and 350 dosage units. Preferably, a set of dosage units is replicated 2 to 12 times.

In suitable embodiments thereof, the estrogen sulphamate and drospirenone is combined in one dosage unit. Alternatively, the estrogen sulphamate and drospirenone is in separate dosage units. That is to say that the kit may comprise dosage units only comprising one if the active agents such as the estrogen sulphamate or the drospirenone. However, in some embodiments the dosage units comprise both the estrogen sulphamate and the drospirenone.

In the embodiment where the dosage units comprises both the estrogen sulphamate and the drospirenone, the pharmaceutical kit may comprise up to 35 dosage units or multiples thereof, wherein at least 3 said dosage units within one multiple of units comprise a

5 combination of an estrogen sulphamate and drospirenone; and wherein optionally up to 32 of said dosage units within one multiple of units comprise a placebo or a blank. Such a kit may further comprise at least one estrogen sulphamate-free dosage unit within one multiple of units, said dosage unit comprising drospirenone. In suitable embodiments, the pharmaceutical kit comprises 4 to 12, preferably 4 to 10, most preferably 4 dosage units
10 within one multiple of units comprising a combination of an estrogen sulphamate and drospirenone

In suitable embodiments of the invention, the pharmaceutical kit comprises dosage units comprising the combination of an estrogen sulphamate and drospirenone as well as

15 estrogen sulphamate-free dosage units comprising drospirenone. Thus, in other embodiments of the invention, the pharmaceutical kit comprises 4 to 10 dosage units within one multiple of units comprising a combination of an estrogen sulphamate and drospirenone and from about 10 to 24, such as 10, 11, 12, 15, 16, 17, 18, 19, 20, 21 or 24 sulphamate-free dosage unit comprising drospirenone

20

In a suitable embodiment of the invention the pharmaceutical kit comprises at least 21 said dosage units comprising a combination of an estrogen sulphamate and drospirenone. This kit may further comprise at least 7 estrogen sulphamate-free dosage units comprising drospirenone.

25

In an alternative embodiment, the pharmaceutical kit further comprises no more than 7 said dosage units within one multiple of units comprising a placebo or a blank. That is to say that these no more than 7 dosage units are substantially free of an estrogen sulphamate and drospirenone.

30

As mentioned, the pharmaceutical kit of the invention may comprise the estrogen sulphamate and the drospirenone in separate dosage units. Such a kit comprises up to 70 dosage units within one multiple of dosage units, wherein at least 3 of those comprises an estrogen sulphamate and another at least three dosage units comprise drospirenone. Such 35 a kit may further comprise at least one dosage unit comprising drospirenone. In another embodiment, such a kit may comprise at least 21 said dosage units comprising an estrogen sulphamate and at least 21 said dosage units comprising drospirenone. This kit may further comprise at least 7 said dosage units comprising drospirenone and still further comprise no more than 7 dosage units comprising a placebo or a blank. In suitable

embodiments of the invention, the kit comprises 4 to 12, such as 4 to 10, preferably 4 dosage units comprising an estrogen sulphamate and 4 to 12, such as 4 to 10, preferably 4 estrogen-sulphamate-free dosage units comprising drospirenone. In other embodiments, the kit comprises 4 to 12, such as 4 to 10, preferably 4 dosage units comprising an 5 estrogen sulphamate and 10 to 30, such as 15 to 30, such as 20 to 28 sulphamate-free dosage unit dosage units comprising drospirenone

The pharmaceutical kit typically comprises of daily dosage units separately packaged as 10 individually removable daily dosage units in a packaging unit and intended for oral administration for a period of at least 28 to 31 consecutive days. The dosage units comprising an estrogen sulphamate and/or drospirenone may comprise varying amounts of 15 said estrogen sulphamate and/or drospirenone. The administration may alternatively be such that the said dosage units are administered once per three days, once per week, once per two week, once per four weeks or once per month. Furthermore some dosage units 20 within a packaging unit may be for daily administration and other dosage units for weekly administration. Alternatively to oral administration, the dosage units may be for transdermal or subcutaneous administration.

According to the invention, the estrogen sulphamate-containing dosage units of the kit 20 comprise estrogen sulphamate in a dose corresponding to about 0.01 to 25 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.05 to 6 mg, more preferably of about 0.1 to 4 mg, even more preferably of about 0.1 to 3 mg, most preferably of about 0.2 to 2 mg. Moreover, the drospirenone-containing dosage units comprise said 25 drospirenone in a dose of about 0.1 to 10 mg, preferably of about 0.25 to 6 mg, more preferably of about 0.25 to 4 mg, even more preferably of about 0.25 to 3 mg, most preferably of about 0.25 to 4 mg.

EXAMPLES

30

Example 1:

Prevention of bone demineralisation

Primary Objective: Bone mineral density after 2 years of treatment.

35

Secondary Objectives: Bone mineral density of the hip after 12, 28, 52, and 80 weeks of treatment. Bone mineral density of the lumbar spine.

The study will be conducted as a double blind, placebo-controlled trial with 100 healthy, post-menopausal women randomly assigned to one of 2 groups of 50 (active or placebo) after giving their informed consent.

5 Active group: 750 µg of estradiol sulphamate + 3 mg drospirenone
Placebo group: placebo tablet

Synopsis

Fifty 20 non-osteopenic patients should be enrolled in each group. All treatments will be
10 applied once per week *per os* during the whole treatment of 2 years without a treatment-free interval. In addition, the patients will be supplied with calcium tablets (500 mg of calcium daily). Measurements of bone mineral density of the hip will be measured on the left side utilising dual-energy x-ray absorptiometry at screening, baseline, and after 12, 28, 52, 80, and 104 weeks of treatment. Biochemical markers of bone remodelling will be
15 measured at intervals.

Evaluation:

The increase of bone mineral density is measured to establish that the density is statistically larger than that observed in the placebo group.

CLAIMS

1. A dosage unit comprising a combination of:
 - i) an estrogen sulphamate; and
 - 5 ii) drospirenone; together with one or more pharmaceutically acceptable carriers or excipients.
2. The dosage unit according to claim 1, wherein the estrogen sulphamate is in a dose sufficient for the treatment of diseases, disorders or symptoms associated with deficient 10 endogenous levels of estrogen in a woman.
3. The dosage unit according to claim 2, wherein the deficient endogenous levels of estrogen are caused by natural menopause, pre-menopause, peri-menopause, post-menopause, hypogonadism, castration, hysterectomy, or primary ovarian failure. 15
4. The dosage unit according to claim 2, wherein the diseases, disorders and symptoms are selected from the group consisting of hot flushes, sweating attacks, palpitations, sleep disorders, mood changes, nervousness, anxiety, poor memory, loss of confidence, loss of libido, poor concentration, diminished energy, diminished drive, irritability, urogenital 20 atrophy, atrophy of the breasts, cardiovascular disease, changes in hair distribution, thickness of hair, changes in skin condition, breast cancer and osteoporosis.
5. The dosage unit according to claim 4, wherein the diseases, disorders and symptoms are selected from the group comprising sleep disorders, mood changes, nervousness, 25 anxiety, urogenital atrophy, atrophy of the breasts, breast cancer, bone demineralisation, and osteoporosis.
6. The dosage unit according to claim 5, wherein the dose of estrogen sulphamate is sufficient for the prevention of bone demineralisation in a woman or for the management 30 of osteoporosis.
7. The dosage unit according to claim 5, wherein the dose of estrogen sulphamate is sufficient for the treatment of breast cancer in a woman, such as estrogen-dependent breast cancer. 35
8. The dosage unit according to claim 1, wherein drospirenone is in a dose sufficient to exhibit its anti-androgenic and/or anti-mineralcorticoid activity.

9. The dosage unit according to claim 8, wherein the anti-androgenic and/or anti-mineralcorticoid activity is selected from the group consisting of prevention or counteraction of the adverse effects of the estrogen sulphamate, such as adverse effects to the endometrium; prevention or lessening of weight gain; prevention or lessening of changes in hair pattern, texture, growth or distribution, such as in hirsutism.
10. The dosage unit according to any one of claims 1 to 9, wherein the estrogen sulphamate is selected from the group consisting of the unsubstituted 17-estradiol-sulphamate, unsubstituted 16,17-estriol-sulphamate, 17-estradiol-3-N,N-dimethyl sulphamate and 16,17-estriol-3-N,N-dimethyl sulphamate, most preferably the unsubstituted 17-estradiol-sulphamate.
11. The dosage unit according to claim 2, wherein the dose of estrogen sulphamate corresponds to a daily delivery of about 0.01 to 1 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.02 to 1 mg or 0.04 to 0.8 mg, more preferably of about 0.06 to 0.6 mg, most preferably of about 0.06 to 0.4 mg of the unsubstituted 17-estradiol-sulphamate.
12. The dosage unit according to claim 2, wherein the dose of estrogen sulphamate corresponds to a three-day delivery of about 0.03 to 3 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.06 to 3 mg or of about 0.1 to 2.5 mg, more preferably of about 0.2 to 1.5 mg, most preferably of about 0.2 to 1 mg of the unsubstituted 17-estradiol-sulphamate.
13. The dosage unit according to claim 2, wherein the dose of estrogen sulphamate corresponds to a weekly delivery of about 0.1 to 6 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.25 to 6 mg or about 0.25 to 4 mg, more preferably of about 0.25 to 3 mg, most preferably of about 0.25 to 2.5 mg or about 0.25 mg to 2 mg of the unsubstituted 17-estradiol-sulphamate.
14. The dosage unit according to claim 2, wherein the dose of estrogen sulphamate corresponds to a delivery of about 0.4 to 25 mg of the unsubstituted 17-estradiol-sulphamate per cycle, preferably of about 0.8 to 16 mg, more preferably of about 0.8 to 12 mg, most preferably of about 0.8 to 10 mg of the unsubstituted 17-estradiol-sulphamate.
15. The dosage unit according to claim 8, wherein the dose of drospirenone corresponds to a daily delivery of about 0.1 mg to 5 mg, preferably 0.25 to 4 mg, more preferably of

about 0.5 to 3 mg or about 0.5 to 2.5 mg, even more preferably of about 0.5 to 1.5 mg, most preferably of about 0.5 to 1 mg of drospirenone.

16. The dosage unit according to claim 8, wherein the dose of drospirenone corresponds to 5 a three-day delivery of about 0.25 mg to 15 mg, preferably of about 0.75 mg to 10 mg or about 1 to 5 mg, more preferably 1, 2, 3, 4, or 5 mg, most preferably of about 2 to 3 mg of drospirenone.
17. The dosage unit according to claim 8, wherein the dose of drospirenone corresponds to 10 a weekly delivery of about 1 mg to 20 mg, preferably 2 mg to 10 mg, more preferably about 2 to 8 mg, most preferably about 3 to 6 mg, such as 3, 4, 5, or 6 mg, most particularly about 4 mg of drospirenone.
18. The dosage unit according to claim 8, wherein the dose of drospirenone corresponds to 15 a delivery of about 2 to 100 mg per cycle, preferably about 5 mg to 50 mg of drospirenone, more preferably about 8 to 30 mg, even more preferably about 10 to 25 mg, most preferably 12 to 20 mg per cycle of drospirenone.
19. The dosage unit according to claim 1 formulated for slow release or normal release of 20 drospirenone.
20. The dosage unit according to claim 1 formulated for slow release or normal release of the estrogen sulphamate.
21. The dosage unit according to any one of the preceding claims, wherein the dose of the estrogen sulphamate is delivered throughout a period selected from 1 day, 3 days, 7 days, 14 days, 28 days and 1 month after administration of one of said dosage unit.
22. The dosage unit according to any one of the preceding claims, wherein the dose of the 30 estrogen sulphamate is sufficient for the treatment of diseases, disorders or symptoms associated with deficient endogenous levels of estrogen in a woman throughout a period selected from 1 day, 3 days, 7 days, 14 days, 28 days and 1 month after administration of one of said dosage unit.
23. The dosage unit according to any one of the preceding claims, wherein the dose of 35 drospirenone is delivered throughout a period selected from 1 day, 3 days, 7 days, 14 days, 28 days and 1 month after administration of one of said dosage unit.

24. The dosage unit according to any one of the preceding claims, wherein the dose of drospirenone is sufficient for exhibiting its anti-androgenic and/or anti-mineralcorticoid activities for a period selected from 1 day, 3 days, 7 days, 14 days, 28 days and 1 month after administration of one of said dosage unit.

5

25. The dosage unit according to any of the preceding claims formulated for oral, topical, transdermal, subcutaneous or parenteral administration, preferably oral administration.

26. The dosage unit according to claim 25, wherein the oral formulation is selected from 10 the group consisting of tablets, capsules, granules and powders.

27. The dosage unit according to claim 25, wherein the transdermal formulation is selected from the group consisting of implantation tablets, oils and implants.

15 28. Use of a combination of drospirenone and an estrogen sulphamate for the preparation of a medicament comprising a sufficient dose of the estrogen sulphamate for the treatment of diseases, disorders or symptoms associated with deficient endogenous levels of estrogen in a woman.

20 29. The use according to claim 28, wherein the estrogen sulphamate is selected from the group consisting of the unsubstituted 17-estradiol-sulphamate, unsubstituted 16,17-estriol-sulphamate, 17-estradiol-3-N,N-dimethyl sulphamate and 16,17-estriol-3-N,N-dimethyl sulphamate, most preferably the unsubstituted 17-estradiol-sulphamate.

25 30. The use according to claim 29, wherein drospirenone or the estrogen sulphamate are delivered in a continuous or discontinuous manner.

31. The use according to any one of claims 29 or 30, wherein the estrogen sulphamate is administered in a sequential manner.

30

32. The use according to claim 31, wherein the estrogen sulphamate is delivered for 18-30 followed by an interruption of delivery of 5-13 days; delivered for 19-28 days followed by an interruption of delivery of 6-12 days; or delivered for 21 days followed by an interruption of delivery of 7 -10 days.

35

33. The use according to claim 30, wherein the estrogen sulphamate is delivered in a continuous manner comprising intervals of administration of 1 to 30 days, preferably 1, 3, 7, 14 or 30 days, more preferably 1, 7, or 30 days, most preferably every 7 days.

34. The use according to any one of claims 30 to 33, wherein drospirenone is delivered in a continuous manner comprising intervals of administration of 1 to 30 days, preferably 1, 3, 7, 14 or 30 days, more preferably 1, 7, or 30 days, most preferably every 1 day.

5 35. The use according to any one of claims 30 to 33, wherein drospirenone is delivered in a discontinuous manner comprising delivering drospirenone for;
1 day followed by an interruption for 1 to 30 days;
2 days followed by an interruption for 1 to 29 days;
3 days followed by an interruption for 1 to 28 days;

10 4 days followed by an interruption for 1 to 27 days;
5 days followed by an interruption for 1 to 26 days;
6 days followed by an interruption for 1 to 25 days;
7 days followed by an interruption for 1 to 24 days;
10 days followed by an interruption for 1 to 21 days;

15 14 days followed by an interruption for 1 to 17 days;
17 days followed by an interruption for 1 to 14 days; or
21 days followed by an interruption for 7 to 10 days;
or combinations thereof.

20 36. The use according to claim 30, wherein the estrogen sulphamate is administered weekly and drospirenone is administered daily.

37. The use according to claim 30, wherein the combination of the estrogen sulphamate and drospirenone is administered weekly.

25 38. The use according to any one of claims 28 to 37, wherein the dose of estrogen sulphamate corresponds to a daily delivery of about 0.01 to 1 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.02 to 1 mg or 0.04 to 0.8 mg, more preferably of about 0.06 to 0.6 mg, most preferably of about 0.06 to 0.4 mg of the unsubstituted 17-estradiol-sulphamate.

30 39. The use according to any one of claims 28 to 37, wherein the dose of estrogen sulphamate corresponds to a three-day delivery of about 0.03 to 3 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.06 to 3 mg or of about 0.1 to 2.5 mg, more preferably of about 0.2 to 1.5 mg, most preferably of about 0.2 to 1 mg of the unsubstituted 17-estradiol-sulphamate.

35 40. The use according to any one of claims 28 to 37, wherein the dose of estrogen sulphamate corresponds to a weekly delivery of about 0.1 to 6 mg of the unsubstituted 17-

estradiol-sulphamate, preferably of about 0.25 to 6 mg or about 0.25 to 4 mg, more preferably of about 0.25 to 3 mg, most preferably of about 0.25 to 2.5 mg or about 0.25 mg to 2 mg of the unsubstituted 17-estradiol-sulphamate.

5 41. The use according to any one of claims 28 to 37, wherein the dose of estrogen sulphamate corresponds to a delivery of about 0.4 to 25 mg of the unsubstituted 17-estradiol-sulphamate per cycle, preferably of about 0.8 to 16 mg, more preferably of about 0.8 to 12 mg, most preferably of about 0.8 to 10 mg of the unsubstituted 17-estradiol-sulphamate.

10

42. The use according to claim 28, wherein drospirenone is in a sufficient dose to exhibit its anti-androgenic and/or anti-mineralcorticoid activity in a woman.

15 43. The use according to claim 42, wherein the dose of drospirenone corresponds to a daily delivery of about 0.1 mg to 5 mg, preferably 0.25 to 4 mg, more preferably of about 0.5 to 3 mg or about 0.5 to 2.5 mg, even more preferably of about 0.5 to 1.5 mg, most preferably of about 0.5 to 1 mg of drospirenone.

20 44. The use according to claim 42, wherein the dose of drospirenone corresponds to a three-day delivery of about 0.25 mg to 15 mg, preferably of about 0.75 mg to 10 mg or about 1 to 5 mg, more preferably 1, 2, 3, 4, or 5 mg, most preferably of about 2 to 3 mg of drospirenone.

25 45. The use according to claim 42, wherein the dose of drospirenone corresponds to a weekly delivery of about 1 mg to 20 mg, preferably 2 mg to 10 mg, more preferably about 2 to 8 mg, most preferably about 3 to 6 mg, such as 3, 4, 5, or 6 mg, most particularly about 4 mg of drospirenone.

30 46. The use according to claim 42, wherein the amount of drospirenone corresponds to a delivery of about 2 to 100 mg per cycle, preferably about 5 mg to 50 mg of drospirenone, more preferably about 8 to 30 mg, even more preferably about 10 to 25 mg, most preferably 12 to 20 mg per cycle of drospirenone.

35 47. The use according to any one of claims 28 to 46, wherein the combination is administered in a single dosage unit or as more than one dosage unit.

48. The use according to any one of claims 28 to 46, wherein the estrogen sulphamate and/or drospirenone are administered in oral, topical, transdermal, subcutaneous, transvaginal or parenteral formulation, or mixtures thereof.

49. The use according to claim 28, wherein the diseases, disorders and symptoms are selected from the group consisting of hot flushes, sweating attacks, palpitations, sleep disorders, mood changes, nervousness, anxiety, poor memory, loss of confidence, loss of 5 libido, poor concentration, diminished energy, diminished drive, irritability, urogenital atrophy, atrophy of the breasts, cardiovascular disease, changes in hair distribution, thickness of hair, changes in skin, breast cancer, bone demineralisation and osteoporosis.

50. The use according to claim 49, wherein the diseases, disorders and symptoms are 10 selected from the group comprising sleep disorders, mood changes, nervousness, anxiety, urogenital atrophy, atrophy of the breasts, breast cancer, bone demineralisation, and osteoporosis.

51. The use according to claim 28, wherein the dose of estrogen sulphamate is sufficient 15 for the prevention of bone demineralisation in a woman or for the management of osteoporosis.

52. The use according to claim 28, wherein the dose of estrogen sulphamate is sufficient 20 for the treatment of breast cancer in a woman, such as estrogen-dependent breast cancer.

53. The use according to any one of claims 28 to 52 for the treatment of a woman in the pre-menopausal or peri-menopausal stage.

54. The use according to claim 53, for the maintenance of menses.

25 55. The use according to claim 42, wherein the anti-androgenic and/or anti-mineralcorticoid activity is selected from the group consisting of prevention or counteraction of the adverse effects of the estrogen sulphamate, such as adverse effects to the endometrium; prevention or lessening of weight gain; prevention or lessening of 30 changes in hair pattern, texture, growth or distribution, such as in hirsutism.

56. The use according to any one of claims 28 to 55, wherein the medicament is a dosage unit as defined in any one of claims 1 to 25 or a pharmaceutical kit as defined in any one of claims 88 to 107.

35 57. A method of treating diseases, disorders and symptoms associated with deficient endogenous levels of estrogen in a woman comprising administering an sufficient dose of estrogen sulphamate to alleviate said diseases, disorders and symptoms in combination with drospirenone.

58. The method according to claim 57, wherein the deficient endogenous levels of estrogen are caused by natural menopause, pre-menopause, peri-menopause, post-menopause, hypogonadism, castration, hysterectomy, or primary ovarian failure.

5

59. The method according to claim 57, wherein the diseases, disorders and symptoms are selected from the group consisting of hot flushes, sweating attacks, palpitations, sleep disorders, mood changes, nervousness, anxiety, poor memory, loss of confidence, loss of libido, poor concentration, diminished energy, diminished drive, irritability, urogenital

10 atrophy, atrophy of the breasts, cardiovascular disease, changes in hair distribution, thickness of hair, changes in skin condition, breast cancer, bone-demineralisation and osteoporosis

15 60. The method according to claim 57, wherein the diseases, disorders and symptoms are selected from the group comprising sleep disorders, mood changes, nervousness, anxiety, urogenital atrophy, atrophy of the breasts, breast cancer, bone demineralisation and osteoporosis.

20 61. The method according to claim 57, wherein the dose of estrogen sulphamate is sufficient for the prevention of bone demineralisation in a woman or for the management of osteoporosis.

25 62. The method according to claim 57, wherein the dose of estrogen sulphamate is sufficient for the treatment of breast cancer in a woman, such as estrogen-dependent breast cancer.

30 63. The method according to claim 57, wherein the estrogen sulphamate is selected from the group consisting of the unsubstituted 17-estradiol-sulphamate, unsubstituted 16,17-estriol-sulphamate, 17-estradiol-3-N,N-dimethyl sulphamate and 16,17-estriol-3-N,N-dimethyl sulphamate, most preferably the unsubstituted 17-estradiol-sulphamate.

35 64. The method according to claim 57, wherein the dose of estrogen sulphamate corresponds to a daily delivery of about 0.01 to 1 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.02 to 1 mg or 0.04 to 0.8 mg, more preferably of about 0.06 to 0.6 mg, most preferably of about 0.06 to 0.4 mg of the unsubstituted 17-estradiol-sulphamate.

65. The method according to claim 57, wherein the dose of estrogen sulphamate corresponds to a three-day delivery of about 0.03 to 3 mg of the unsubstituted 17-

estradiol-sulphamate, preferably of about 0.06 to 3 mg or of about 0.1 to 2.5 mg, more preferably of about 0.2 to 1.5 mg, most preferably of about 0.2 to 1 mg of the unsubstituted 17-estradiol-sulphamate.

5 66. The method according to claim 57, wherein the dose of estrogen sulphamate corresponds to a weekly delivery of about 0.1 to 6 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.25 to 6 mg or about 0.25 to 4 mg, more preferably of about 0.25 to 3 mg, most preferably of about 0.25 to 2.5 mg or about 0.25 mg to 2 mg of the unsubstituted 17-estradiol-sulphamate.

10

67. The method according to claim 57, wherein the dose of estrogen sulphamate corresponds to a delivery of about 0.4 to 25 mg of the unsubstituted 17-estradiol-sulphamate per cycle, preferably of about 0.8 to 16 mg, more preferably of about 0.8 to 12 mg, most preferably of about 0.8 to 10 mg of the unsubstituted 17-estradiol-sulphamate.

15

68. The method according to claim 57, wherein drospirenone is in a sufficient dose to exhibit its anti-androgenic and/or anti-mineralcorticoid activity in a woman.

20 69. The method according to claim 68, wherein the dose of drospirenone corresponds to a daily delivery of about 0.1 mg to 5 mg, preferably 0.25 to 4 mg, more preferably of about 0.5 to 3 mg or about 0.5 to 2.5 mg, even more preferably of about 0.5 to 1.5 mg, most preferably of about 0.5 to 1 mg of drospirenone.

25 70. The method according to claim 68, wherein the dose of drospirenone corresponds to a three-day delivery of about 0.25 mg to 15 mg, preferably of about 0.75 mg to 10 mg or about 1 to 5 mg, more preferably 1, 2, 3, 4, or 5 mg, most preferably of about 2 to 3 mg.

71. The method according to claim 68, wherein the dose of drospirenone corresponds to a
30 weekly delivery of about 1 mg to 20 mg, preferably 2 mg to 10 mg, more preferably about 2 to 8 mg, most preferably about 3 to 6 mg, such as 3, 4, 5, or 6 mg, most particularly about 4 mg of drospirenone.

72. The method according to claim 68, wherein the amount of drospirenone corresponds to
35 a delivery of about 2 to 100 mg per cycle, preferably about 5 mg to 50 mg of drospirenone, more preferably about 8 to 30 mg, even more preferably about 10 to 25 mg, most preferably 12 to 20 mg per cycle of drospirenone.

73. The method according to claim 57, wherein the combination is administered in a single dosage unit or as more than one dosage unit.

74. The method according to claim 73, wherein estrogen sulphamate and drospirenone are 5 concomitantly or independently administered in a continuous or discontinuous manner.

75. The method according to claim 74, wherein the estrogen sulphamate is administered in a continuous manner and drospirenone in a discontinuous manner.

10 76. The method according to claim 75, wherein the estrogen sulphamate is delivered in a sequential manner.

77. The method according to claim 76, wherein the estrogen sulphamate is delivered for 18-30 followed by an interruption of delivery of 5-13 days;

15 delivered for 19-28 days followed by an interruption of delivery of 6-12 days; or delivered for 21 days followed by an interruption of delivery of 7 -10 days.

78. The method according to claim 74, wherein the continuous manner comprises intervals of administration of 1 to 30 days, preferably 1, 3, 7, 14, or 30 days, most preferably 1, 7, 20 or 30 days.

79. The method according to claim 68, wherein drospirenone is delivered in a discontinuous manner comprising delivering drospirenone for;

1 day followed by an interruption for 1 to 30 days;

25 2 days followed by an interruption for 1 to 29 days;

3 days followed by an interruption for 1 to 28 days;

4 days followed by an interruption for 1 to 27 days;

5 days followed by an interruption for 1 to 26 days;

6 days followed by an interruption for 1 to 25 days;

30 7 days followed by an interruption for 1 to 24 days;

10 days followed by an interruption for 1 to 21 days;

14 days followed by an interruption for 1 to 17 days;

17 days followed by an interruption for 1 to 14 days; or

21 days followed by an interruption for 7 to 10 days;

35 or combinations thereof.

80. The method according to claim 57, wherein the estrogen sulphamate is administered weekly and drospirenone is administered daily.

81. The method according to claim 57, wherein the combination of the estrogen sulphamate and drospirenone is administered weekly.

82. The method according to claim 57, wherein the estrogen sulphamate and/or drospirenone are administered in oral, topical, transdermal, subcutaneous, transvaginal or parenteral formulation, or mixtures thereof.

83. The method according to claim 82, wherein the estrogen sulphamate and/or drospirenone are administered in oral formulation or transdermal formulation, preferably oral formulation.

84. The method according to claim 83, wherein the estrogen sulphamate and/or drospirenone are administered in oral formulation, from a patch, from an implant or combinations thereof.

15 85. The method according to claim 57, wherein the combination of the estrogen sulphamate and drospirenone is administered as a dosage unit as defined by any one of claims 1 to 24 or as a pharmaceutical kit as defined in any one of claims 86 to 104.

20 86. The method according to claim 57, wherein the combination of the estrogen sulphamate and drospirenone is administered for 1 to 12, preferably 2 to 6, such as 2, 3, 4, 5, and 6 multiples of 28 to 35 days.

25 87. The method according to claim 57, wherein the combination of the estrogen sulphamate and drospirenone is administered weekly for 1 to 6, preferably 1 to 4, such as 1, 2, 3 and 4 multiples of 4 to 12 weeks.

30 88. The method according to claim 68, wherein the anti-androgenic and/or anti-mineralcorticoid activity is selected from the group consisting of prevention or counteraction of the adverse effects of the estrogen sulphamate, such as adverse effects to the endometrium; prevention or lessening of weight gain; prevention or lessening of changes in hair pattern, texture, growth or distribution, such as in hirsutism.

35 89. A pharmaceutical kit comprising up to 70 dosage units or multiples thereof, wherein at least 3 said dosage units within one multiple of units comprise an estrogen sulphamate and at least 3 said dosage units within one multiple of units comprise drospirenone; and wherein optionally up to 64 of said dosage units within one multiple of units comprise a placebo or a blank.

90. The pharmaceutical kit according to claim 89, wherein said dosages units comprises a combination of the estrogen sulphamate and drospirenone.

91. The pharmaceutical kit according to claim 89, wherein the estrogen sulphamate and drospirenone is in separate dosage units.

92. The pharmaceutical kit according to claim 90 comprising up to 35 dosage units or multiples thereof, wherein at least 3 said dosage units within one multiple of units comprise a combination of an estrogen sulphamate and drospirenone; and wherein 10 optionally up to 32 of said dosage units within one multiple of units comprise a placebo or a blank.

93. The pharmaceutical kit according to claim 92, further comprising at least one estrogen sulphamate-free dosage unit within one multiple of units, said dosage unit comprising 15 drospirenone.

94. The pharmaceutical kit according to claim 93, wherein at least 21 said dosage units within one multiple of units comprise a combination of the estrogen sulphamate and drospirenone.

20

95. The pharmaceutical kit according to claim 94, further comprising at least 7 estrogen sulphamate-free dosage units within one multiple of units said dosage unit comprising drospirenone.

25 96. The pharmaceutical kit according to any of claims 94 or 95, further comprising no more than 7 dosage units within one multiple of units comprising a placebo or a blank.

97. The pharmaceutical kit according to claim 91, further comprising at least one dosage unit comprising drospirenone.

30

98. The pharmaceutical kit according to claim 91, wherein within one multiple of units at least 21 said dosage units comprise estrogen sulphamate and at least 21 said dosage units comprise drospirenone.

35 99. The pharmaceutical kit according to claim 98, further comprising within one multiple of units at least 7 said dosage units comprising drospirenone.

100. The pharmaceutical kit according to claim 99, further comprising no more than 7 dosage units within one multiple of units comprising a placebo or a blank.

101. The pharmaceutical kit according to claim 100, wherein within each multiple of units at least 3 dosage units comprise the estrogen sulphamate and at least 21 dosage units comprise drospirenone.

5

102. The pharmaceutical kit according to any of claims 89 to 101, wherein the estrogen sulphamate is selected from the group consisting of the unsubstituted 17-estradiol-sulphamate, unsubstituted 16,17-estriol-sulphamate, 17-estradiol-3-N,N-dimethyl sulphamate and 16,17-estriol-3-N,N-dimethyl sulphamate, most preferably the

10 unsubstituted 17-estradiol-sulphamate.

103. The pharmaceutical kit according to any of claims 89 to 102, wherein the estrogen sulphamate is the unsubstituted 17-estradiol-sulphamate.

15 104. The pharmaceutical kit according to any one of claims 89 to 103, wherein said estrogen sulphamate-containing dosage units comprise said estrogen sulphamate in a dose corresponding to about 0.01 to 25 mg of the unsubstituted 17-estradiol-sulphamate, preferably of about 0.05 to 6 mg, more preferably of about 0.1 to 4 mg, even more preferably of about 0.1 to 3 mg, most preferably of about 0.2 to 2 mg.

20

105. The pharmaceutical kit according to any one of claims 89 to 103, wherein said drospirenone-containing dosage units comprise said drospirenone in a dose of about 0.1 to 10 mg, preferably of about 0.25 to 6 mg, more preferably of about 0.25 to 4 mg, even more preferably of about 0.25 to 3 mg, most preferably of about 0.25 to 4 mg.

25

106. The pharmaceutical kit according to any one of claims 89 to 105, wherein the dosage units comprising the estrogen sulphamate and/or drospirenone comprise varying doses of said estrogen sulphamate and/or drospirenone.

30 107. The pharmaceutical kit according to any one of claims 89 to 106, wherein the said dosage units are administered once per day, once per three days, once per week, once per two week, once per four weeks, once per month or combination thereof.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 02/03354A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K31/565 A61K31/58

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DE 44 29 398 A (JENAPHARM GMBH) 15 February 1996 (1996-02-15)</p> <p>claim 2 page 7, line 9 page 7, line 12 page 7, line 44,45,50</p> <p>---</p> <p>-/-</p>	<p>1-5,7,8, 10-20, 25,26, 28-30, 38-50, 52,53, 56,57, 59,60, 62-74, 82-85</p>

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

14 November 2002

25/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Beranová, P

INTERNATIONAL SEARCH REPORT

Inte al Application No
PCT/IB 02/03354

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 05064 A (IMPERIAL COLLEGE) 18 March 1993 (1993-03-18) cited in the application claim 2 page 8, line 8 - line 12 -----	

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 02/03354

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 57 – 88 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte
Application No
PCT/IB 02/03354

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE 4429398	A 15-02-1996	DE 4429398 A1 AU 2974295 A BG 63273 B1 BG 101190 A BR 9508868 A CA 2196678 A1 CN 1160404 A CZ 9700273 A3 DE 4447714 C2 DE 4447715 C2 WO 9605217 A1 EP 0775156 A1 JP 10507741 T KR 243537 B1 NO 970569 A PL 318530 A1 RU 2179442 C2 SG 33434 A1 SK 16297 A3 US 2002061868 A1	15-02-1996 07-03-1996 31-08-2001 31-03-1998 28-10-1997 22-02-1996 24-09-1997 13-08-1997 05-02-1998 05-02-1998 22-02-1996 28-05-1997 28-07-1998 01-02-2000 08-04-1997 23-06-1997 20-02-2002 18-10-1996 06-08-1997 23-05-2002
WO 9305064	A 18-03-1993	AT 194843 T AU 717116 B2 AU 1007799 A AU 668882 B2 AU 2490592 A AU 689043 B2 AU 5837396 A AU 7195298 A BR 9206434 A CA 2114630 A1 CA 2305749 A1 CA 2305758 A1 CA 2305767 A1 CZ 9400440 A3 DE 69231280 D1 DE 69231280 T2 DK 641355 T3 EP 1099706 A2 EP 0641355 A1 EP 0928609 A2 EP 0921130 A2 EP 0982032 A2 ES 2148178 T3 FI 940903 A FI 20002259 A FI 20002260 A FI 20002261 A WO 9305064 A1 GR 3034579 T3 HU 66097 A2 JP 2000038341 A JP 7501515 T JP 3219408 B2 JP 2000355542 A JP 2000355598 A JP 2002255993 A KR 258396 B1	15-08-2000 16-03-2000 04-03-1999 23-05-1996 05-04-1993 19-03-1998 05-09-1996 13-08-1998 27-09-1994 18-03-1993 18-03-1993 18-03-1993 18-03-1993 18-01-1995 24-08-2000 30-11-2000 09-10-2000 16-05-2001 08-03-1995 14-07-1999 09-06-1999 01-03-2000 16-10-2000 20-04-1994 13-10-2000 13-10-2000 13-10-2000 18-03-1993 31-01-2001 28-09-1994 08-02-2000 16-02-1995 15-10-2001 26-12-2000 26-12-2000 11-09-2002 01-08-2000

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IB 02/03354

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9305064	A	LV 12618 A	20-02-2001
		LV 12618 B	20-07-2001
		NO 940635 A	29-04-1994
		NO 995075 A	29-04-1994
		NO 995076 A	29-04-1994
		NO 2595 A	29-04-1994
		RU 2182152 C2	10-05-2002
		SG 88782 A1	21-05-2002
		SG 88783 A1	21-05-2002
		SK 24694 A3	09-11-1994
		SK 282187 B6	03-12-2001
		SK 282188 B6	03-12-2001